Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04583735 · ClinicalTrials.gov registry record · Phase 4
A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease
A Phase 4 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 4
- Development phase
- 62
- Enrollment target
NCT04583735 is a Phase 4 study that has completed, run by Amgen. The registered enrollment target is 62 participants.
The verdict
NCT04583735, a Phase 4 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 62 participants
- Enrollment target
Study Summary
The overall objective is to investigate the efficacy, safety and tolerability of TEPEZZA® in participants with chronic (inactive) TED (thyroid eye disease). Approximately 57 participants will be enrolled. There will be a treatment period (through Week 24) and a follow up period (where TEPEZZA will not be infused).
Interventions
- DRUG Placebo
- BIOLOGICAL TEPEZZA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2021-09-02 |
| Est. Completion | 2023-10-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04583735
The ClinicalTrials.gov registry entry for NCT04583735 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04583735 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04583735 about?
NCT04583735 is a clinical study titled "A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease". The overall objective is to investigate the efficacy, safety and tolerability of TEPEZZA® in participants with chronic (inactive) TED (thyroid eye disease). Approximately 57 participants will be enrolled. There will be a treatment period (through Week 24) and a follow up period (where TEPEZZA will n...
What is the current status of trial NCT04583735?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 62 participants. The study started on 2021-09-02. Estimated completion is 2023-10-12.
What interventions are being tested in trial NCT04583735?
The interventions under investigation include: Placebo (DRUG), TEPEZZA (BIOLOGICAL).
Who is sponsoring clinical trial NCT04583735?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.